CStone Pharmaceuticals, a biopharma company focused on developing and commercialising innovative immuno-oncology and molecularly targeted drugs, announced today that it has named Archie Tse, MD, PhD as its new senior vice president, chief translational medicine officer.

Dr Tse is to report to Frank Jiang, MD, PhD, chairman and chief executive officer.

Dr Tse has more than 20 years of global oncology research and clinical development experience and the company says that he will provide a strong addition to its senior leadership team. In this role, Dr Tse will be responsible for the development of assets at the early clinical development stage up to proof of concept. He will manage the development and implementation of clinical biomarkers to support progression of CStone's pipelines. His in-depth understanding of the global oncology space is intended to help further strengthen CStone's core competence and solidify its position among innovative biopharma companies in China.